Drug extends survival in lung cancer patients
Combination extends survival vs. standard first-line therapy for advanced lung cancer
A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung cancer, according to the agents’ manufacturer.The OS benefit with amivantamab-vmjw (Rybrevant,
Drug extends survival in lung cancer patients: J&J
Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung cancer that has specific epidermal growth factor receptor mutations.
Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...
Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.
In this edition of InnovationRx, medical debts will be erased from credit histories, this farm is doubling down on raw milk ...
Dame Esther responded after a columnist tried to use her own cancer experience as an argument against assisted dying.
The other day, Dame Esther Rantzen announced some wonderful news. In an article she’d written for a national newspaper, ...
Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...
Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved Rybrevant ...
Limited (HUTCHMED) (HCM) announced that the New Drug Application (NDA) for the combination of ORPATHYS(savolitinib) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback